Skip to main content

Table 1 Clinicopathologic characteristics of study population

From: Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles

Characteristics All
(n = 135)
Extended chemotherapy (n = 52) Standard chemotherapy (n = 83) P
Age at initial diagnosis, years 55.5 ± 10.1 55.0 ± 9.0 55.9 ± 10.7 0.624
Age at 1st recurrence, years 57.4 ± 9.9 56.6 ± 9.1 57.9 ± 10.4 0.475
Primary site of disease     0.314
 Ovary 123 (91.1) 46 (88.5) 77 (92.8)  
 Tube 4 (3.0) 1 (1.9) 3 (3.6)  
 Peritoneum 8 (5.9) 5 (9.6) 3 (3.6)  
Histologic type     0.344
 Serous 120 (88.9) 46 (88.5) 74 (89.2)  
 Endometrioid 8 (5.9) 3 (5.8) 5 (6.0)  
 Mucinous 1 (0.7) 1 (1.9) 0  
 Clear cell 3 (2.2) 2 (3.8) 1 (1.2)  
 Mixed 3 (2.2) 0 3 (3.6)  
Grade     0.136
 1 4 (3.0) 3 (5.8) 1 (1.2)  
 2 7 (5.2) 1 (1.9) 6 (7.2)  
 3 124 (91.9) 48 (92.3) 76 (91.6)  
FIGO stage     0.496
 I-II 9 (6.7) 5 (9.6) 4 (4.8)  
 III 88 (65.2) 34 (65.4) 54 (6.1)  
 IV 38 (28.1) 13 (25.0) 25 (30.1)  
Primary treatment strategy     0.540
 PDS 100 (74.1) 37 (71.2) 63 (75.9)  
 NAC 35 (25.9) 15 (28.8) 20 (24.1)  
Results of initial debulking surgery     0.041
 Complete gross resection 72 (53.3) 22 (42.3) 50 (60.2)  
 Residual tumor <1 cm 36 (26.7) 20 (38.5) 16 (19.3)  
 Residual tumor ≥1 cm 27 (20.0) 10 (19.2) 17 (20.5)  
Platinum-free interval, months
 Median (range) 12.5 (6.0–87.9) 11.0 (6.2–87.9) 13.1 (6.0–84.5) 0.018
 6–12, partially platinum-sensitive 61 (45.2) 28 (53.8) 33 (39.8) 0.109
 ≥12, totally platinum-sensitive 74 (54.8) 24 (46.2) 50 (60.2)  
CA-125 at 1st recurrence, IU/mL     0.152
 Median (range) 91.0 (7.9–6290.0) 99.1 (12.0–6290.0) 91.0 (7.9–1908.0)  
Secondary debulking surgery     0.003
 No 118 (87.4) 51 (98.1) 67 (80.7)  
 Yes 17 (12.6) 1 (1.9) 16 (19.3)  
Results of secondary debulking surgery     0.279
 Complete gross resection 6 (4.4) 0 6 (7.2)  
 Residual tumor <1 cm 6 (4.4) 0 6 (7.2)  
 Residual tumor ≥1 cm 5 (3.7) 1 (1.9) 4 (4.8)  
Residual tumor on CT after #6     0.232
 ≥0.5 cm and <1 cm 65 (48.1) 28 (53.8) 37 (44.6)  
 ≥1 cm and <2 cm 56 (41.5) 17 (32.7) 39 (47.0)  
 ≥2 cm 14 (10.4) 7 (13.5) 7 (8.4)  
CA-125 after #6, IU/mL     0.122
 Median (range) 12.5 (1.1–445.0) 14.0 (1.1–249.0) 11.0 (1.1–445.0)  
Maintenance therapy
 No 98 (72.6) 46 (88.5) 52 (62.7) 0.001
 Yes 37 (27.4) 6 (11.5) 31 (37.3)  
  Bevacizumab 29 (21.5) 5 (9.6) 24 (28.9) >0.999
  Olaparib 8 (5.9) 1 (1.9) 7 (8.4)  
Germline BRCA1/2 gene test
 Not performed 51 (37.8) 23 (44.2) 28 (33.7) 0.221
 Performed 84 (62.2) 29 (55.8) 55 (66.3)  
  Wild-type 58 (43.0) 21 (40.4) 37 (44.6) 0.628
  Mutation 26 (19.3) 8 (15.4) 18 (21.7)  
  1. Values are presented as mean ± standard deviation or n (%) unless otherwise indicated
  2. Abbreviations: CA-125 Cancer antigen 125, CT Computed tomography, FIGO International Federation of Gynecology and Obstetrics
\